Global Primary Mitochondrial Myopathies - Pipeline Insight, 2022

This “Primary Mitochondrial Myopathies - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Primary Mitochondrial Myopathies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary Mitochondrial Myopathies Understanding

Primary Mitochondrial Myopathies: Overview

Primary mitochondrial myopathies (PMM) are a group of disorders that are associated with changes in genetic material (e.g. depletions, deletions, or mutations) found within the DNA of mitochondria (mtDNA) or with genes outside the mitochondria (nuclear DNA), affecting predominantly the skeletal muscle. Mitochondria, found by the hundreds within every cell of the body, regulate the production of cellular energy and carry the genetic blueprints for this process within their own unique DNA (mtDNA). These disorders often hamper the ability of affected cells to break down food and oxygen and produce energy. Mitochondria provide more than 90% of the energy used by the body's tissues; mitochondrial disorders are characterized by a lack of sufficient energy for cells of the body to function properly. High-energy tissues like muscle, brain, or heart tissue are most likely to be affected by mitochondrial disorders. In most mitochondrial disorders, abnormally high numbers of defective mitochondria are present in the cells of the body. Mitochondrial diseases often affect more than one organ system of the body. Most mitochondrial diseases affect the muscles (myopathy). Sometimes, muscle disease is the only or predominant sign of a mitochondrial disorder, thus defined as PMM. There are no disease-modifying treatments for PMM; treatment is aimed to improving or resolving specific symptoms.

"Primary Mitochondrial Myopathies - Pipeline Insight, 2022" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Mitochondrial Myopathies pipeline landscape is provided which includes the disease overview and Primary Mitochondrial Myopathies treatment guidelines. The assessment part of the report embraces, in depth Primary Mitochondrial Myopathies commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Mitochondrial Myopathies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Primary Mitochondrial Myopathies.
• In the coming years, the Primary Mitochondrial Myopathies market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Primary Mitochondrial Myopathies R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Primary Mitochondrial Myopathies treatment market. Several potential therapies for Primary Mitochondrial Myopathies are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Primary Mitochondrial Myopathies market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Primary Mitochondrial Myopathies) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Primary Mitochondrial Myopathies Emerging Drugs Chapters

This segment of the Primary Mitochondrial Myopathies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Mitochondrial Myopathies Emerging Drugs

REN001: Reneo Pharma

LtdREN001 is an investigational clinical-stage compound known to control a number of genes involved in the mitochondrial activity. Reneo is developing this compound to improve cellular energy metabolism by enhancing mitochondrial function and potentially increasing the number of mitochondria. The company completed a Phase 1b clinical trial of REN001 in patients with PMM and myopathy with mitochondrial DNA (mtDNA) mutations. The primary objective of the trial was to evaluate the safety and tolerability of REN001, and we also included measures of clinical outcome such as exercise tests and symptom questionnaires. REN001 was generally well tolerated with no drug related serious adverse events (SAE) observed. Improvements were observed in exercise tests and symptoms questionnaires.

Elamipretide: Stealth

BioTherapeuticsElamipretide, is a peptide compound that readily penetrates cell membranes, and targets the inner mitochondrial membrane where it binds reversibly to cardiolipin. In preclinical or clinical studies, it was observed that elamipretide increases mitochondrial respiration, improves electron transport chain function and ATP production and reduces formation of pathogenic ROS levels. This elamipretide-cardiolipin association has been shown to normalize the structure of the inner mitochondrial membrane, thereby improving mitochondrial function. Functional benefit is achieved through improvement of ATP production and interruption and potential reversal of damaging oxidative stress. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Primary Mitochondrial Myopathy.

Primary Mitochondrial Myopathies: Therapeutic Assessment

This segment of the report provides insights about the different Primary Mitochondrial Myopathies drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Primary Mitochondrial Myopathies

There are approx. 3+ key companies which are developing the therapies for Primary Mitochondrial Myopathies. The companies which have their Primary Mitochondrial Myopathies drug candidates in the most advanced stage, i.e. phase III include, Stealth BioTherapeutics.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Primary Mitochondrial Myopathies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Mitochondrial Myopathies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Mitochondrial Myopathies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Mitochondrial Myopathies drugs.

Primary Mitochondrial Myopathies Report Insights

• Primary Mitochondrial Myopathies Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary Mitochondrial Myopathies Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary Mitochondrial Myopathies drugs?
• How many Primary Mitochondrial Myopathies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Mitochondrial Myopathies?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Mitochondrial Myopathies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Mitochondrial Myopathies and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Reneo Pharma Ltd
• Stealth BioTherapeutics
• Astellas Pharma Inc
• Abliva AB

Key Products

• REN001
• Elamipretide
• Bocidelpar
• KL 1333